With over 30 years of experience in Biotech, with much of that dedicated to the discovery and development of ADCs, Iksuda is privileged to have Bob as its CSO.

Whilst serving as VP Translational R&D at ImmunoGen, Bob was directly responsible for the development of all ADC programs, including Kadcyla - the first ADC to be approved for solid tumor indications.